UPDATE: Cowen Starts Novavax (NVAX) at Outperform

January 21, 2022 5:56 AM EST
Get Alerts NVAX Hot Sheet
Price: $58.43 +12.13%

Rating Summary:
    9 Buy, 4 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 4 | Down: 15 | New: 7
Trade Now! 
Join SI Premium – FREE
(Updated - January 21, 2022 6:01 AM EST)

Cowen analyst Georgi Yordanov initiates coverage on Novavax (NASDAQ: NVAX) with a Outperform rating.

The analyst comments "Novavax is entering the competitive COVID-19 vaccine market with a differentiated profile with improved tolerability compared to the mRNA options. Given the near-term cashflow from APAs and the potential to capture a share of what we believe will be an eventual post-pandemic annual vaccination market, we initiate at Outperform with a PT of $150. NanoFlu should provide downside protection."

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $90.36 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Cowen & Co